UBS Group Increases Iqvia (NYSE:IQV) Price Target to $200.00

Iqvia (NYSE:IQV) had its target price boosted by UBS Group from $187.00 to $200.00 in a research report report published on Thursday morning, BenzingaRatingsTable reports. They currently have a buy rating on the medical research company’s stock.

Several other equities analysts also recently weighed in on the company. Cfra raised Iqvia from a hold rating to a buy rating and boosted their target price for the company from $148.00 to $185.00 in a research report on Wednesday. Credit Suisse Group reissued a buy rating and set a $170.00 target price on shares of Iqvia in a research report on Friday, December 20th. Zacks Investment Research raised Iqvia from a sell rating to a hold rating and set a $170.00 target price on the stock in a research report on Tuesday, February 4th. ValuEngine downgraded Iqvia from a hold rating to a sell rating in a research report on Tuesday, February 4th. Finally, Wolfe Research raised Iqvia from a peer perform rating to an outperform rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $174.30.

Shares of NYSE IQV traded down $1.47 during trading hours on Thursday, hitting $164.32. 2,962,308 shares of the company traded hands, compared to its average volume of 1,312,776. The stock has a market capitalization of $31.03 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85. The company’s 50 day moving average price is $158.20 and its 200 day moving average price is $151.72. Iqvia has a 12 month low of $130.77 and a 12 month high of $169.14.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The firm had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.50 EPS. Equities analysts anticipate that Iqvia will post 5.9 EPS for the current year.

In other news, CFO Michael R. Mcdonnell sold 12,000 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the transaction, the chief financial officer now owns 14,366 shares of the company’s stock, valued at approximately $2,227,735.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael J. Evanisko sold 6,250 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $155.19, for a total value of $969,937.50. The disclosure for this sale can be found here. Insiders sold a total of 37,000 shares of company stock worth $5,830,215 in the last ninety days. 6.00% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Penserra Capital Management LLC grew its position in shares of Iqvia by 57.5% during the 4th quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Usca Ria LLC bought a new position in shares of Iqvia during the 3rd quarter worth $29,000. Patriot Financial Group Insurance Agency LLC grew its position in shares of Iqvia by 379.5% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock worth $33,000 after buying an additional 167 shares in the last quarter. Evolution Wealth Advisors LLC grew its position in shares of Iqvia by 303.6% during the 4th quarter. Evolution Wealth Advisors LLC now owns 222 shares of the medical research company’s stock worth $34,000 after buying an additional 167 shares in the last quarter. Finally, Citizens Financial Group Inc RI bought a new position in shares of Iqvia during the 4th quarter worth $34,000. 89.93% of the stock is currently owned by institutional investors and hedge funds.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: Sell-Side Analysts

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.